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Abstract
Inclusion Body Myositis (IBM) is a relatively common acquired inflammatory
myopathy in patients above 50 years of age. Pathological hallmarks of IBM are
intramyofiber protein inclusions and endomysial inflammation, indicating that
both myodegenerative and inflammatory mechanisms contribute to its patho-
genesis. Impaired protein degradation by the autophagic machinery, which
regulates innate and adaptive immune responses, in skeletal muscle fibers has
recently been identified as a potential key pathomechanism in IBM.
Immunotherapies, which are successfully used for treating other inflammatory
myopathies lack efficacy in IBM and so far no effective treatment is available.
Thus, a better understanding of the mechanistic pathways underlying progres-
sive muscle weakness and atrophy in IBM is crucial in identifying novel
promising targets for therapeutic intervention. Here, we discuss recent insights
into the pathomechanistic network of mutually dependent inflammatory and
degenerative events during IBM.
Introduction
Inclusion body myositis (IBM) is a progressive slow-onset
inflammatory myopathy that is characterized by the con-
comitant presence of multi-focal myofiber-surrounding
lymphocytic infiltrates as well as vacuolar myodegenera-
tion.1–4 Together with dermatomyositis (DM), polymyosi-
tis (PM), necrotizing autoimmune myositis (NAM) and
overlap myositis (OM), IBM belongs to the heterogenous
group of inflammatory myopathies and, amongst individu-
als 50 years of age and older, it is considered as a relatively
frequent disorder.3,5 The underlying interrelationship
between the inflammatory component of the disease and
the observed multi-protein aggregation remains elusive and
subject to vigorous debate.3,6–8 Unlike other inflammatory
myopathies, IBM presents mainly refractory toward
immunosuppressive therapy and at present, there is no
effective treatment available.5,9,10 In this review, we will
focus on the current knowledge about the interrelationship
of inflammatory and myodegenerative pathomechanisms
in IBM.
Clinical Presentation
The disease commonly commences slowly-progressive,
sometimes over decades. The clinical presentation is
heterogenous and at times difficult to distinguish from
other inflammatory myopathies (muscle weakness and
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atrophy), motor-neuron disease (asymmetry), and muscu-
lar dystrophies (slowly progressive disease).3 In two large
observational studies, the mean age of onset has been
reported to be 59  9 and 61 years, respectively.9,11 The
cardinal symptom of this highly debilitating disease is the
late-onset steady acquisition of muscular weakness and
atrophy over a long period of time whilst sensory func-
tion is completely preserved. The decline of muscle
strength ranges between 3.5 and 5.5% per annum.9,11
Unlike other myopathies, during which proximal muscles
are initially affected, IBM shows early involvement of dis-
tal muscles. Classical manifestation patterns frequently
include the quadriceps, deep finger flexors, foot extensors,
and often presents asymmetrically at the beginning. Fre-
quent falls may be an early clinical sign of IBM. Para-
spinal and axial muscles may be affected, resulting in
head drop and camptocormia.12 Depending on the study,
oropharyngeal dysphagia is reported in up to 40–86% of
IBM cases, mostly due to upper esophageal sphincter dys-
function.13–16 It develops insidiously, leading to frequent
choking episodes and is, alongside pneumonia as a result
of immobility, considered to be a potentially fatal compli-
cation of IBM. Importantly, dysphagia may be an isolated,
initial manifestation and IBM should be considered by
the examining physician as differential diagnosis for new
onset of dysphagia in the elderly.13,14,17–21 Early in the
disease course, tendon reflexes remain unaffected, how-
ever, hyporeflexia may occur at later stages of the disease
due to significant muscle atrophy.19 The heart muscle
remains usually unaffected and the incidence of cardial
muscle abnormalities does not exceed the expected inci-
dence for the respective age group.22 There is no evidence
for increased cancer risk in IBM patients.23
Epidemiology
IBM affects males more frequently (3:1), shows an overall
prevalence of approximately 4-15/1000000 (35-71/
1000000 > age 50, respectively), is noticably frequent in
Western Australia, Japan, Norway, Olmsted County (Min-
nesota, USA), and is especially rare in Turkey and
India.3,24–31 In Japan, the number of diagnosed IBM cases
has steadily increased since 1991, whereas the number of
PM cases has remained constant.32 Prolonged life span
and concomitant increase of the fraction of elderly people
as well as westernization of dietary habits in Japan might
be contributing factors for this observation.33 Although it
was suggested that mortality is increased in IBM patients,
solid evidence is still insufficient and the matter remains
subject to larger studies.17,34
Current data prompt that IBM meets the criteria to be
catagorized as an orphan disease. However, it is likely that
the prevalence of IBM is still underestimated. Although
heavily debated, it is conceivable that a significant number
of patients diagnosed with PM might in fact suffer from
IBM.35–38 Aside from erroneous diagnoses, the slowly pro-
gressive nature of the disease course and the heterogenicity
in its clinical presentation make the condition prone to
delayed diagnosis. Increasing awareness and continous
efforts to optimize diagnostic criteria for IBM are of utmost
importance in ensuring ample care to patients.
Diagnosis
The chronic disease progression of IBM makes it chal-
lenging to detect the condition at an early time point and
on average there is a 5-year delay in diagnosis.9,39 Crea-
tine kinase levels in serum can be normal to only mildly
elevated and will not exceed 10-fold increase above the
upper limit of normal. Muscle biopsies of affected areas
typically show CD8+ T cells surrounding nonnecrotic,
healthy appearing muscle fibers that express major histo-
compatibility complex (MHC) class I. Additionally,
ragged-red-, ragged-blue- and cytochrome oxidase-nega-
tive fibers, as well as autophagic vacuoles and congophilic
amyloid deposits are regularly observed.3
The original diagnostic criteria according to Griggs
et al. strongly relied on histopathological features of the
disease.40 However, it is now apparent that a given muscle
biopsy will rarely show all pathological changes that go
along with IBM. Basing a definitive diagnosis on the pre-
requisite of detecting all formerly described histopatho-
logical alterations will likely lead to underdiagnosis of the
disease. It has been previously described that some
patients that fit clinical categorization of IBM, lack
canonical biopsy features of IBM.41 It has become clear
that histopathological abnormalities in IBM are likely to
appear scattered and patchy in a spatio-temporal manner.
The increasing research efforts over the past 45 years,
together with accumulated clinical experience, allows
physicians today to reliably diagnose the disease not
exclusively due to histopathological changes in muscle
biopsies but rather through an integrated approach, using
clinical and histological observations alike. Therefore,
more recently defined diagnostic criteria do not call for
the presence of all typical pathological hallmarks but
employ the presence of defined patterns of clinical, labo-
ratory, and histological features to categorize the diagno-
sis into either clinicopathologically defined IBM, clinically
defined IBM or probable IBM.12,42 One study applying
machine learning algorithms to construct data-derived
IBM diagnostic criteria claims that the combinational
approach of finger flexor or quadriceps weakness, endo-
mysial inflammation, and either invasion of nonnecrotic
muscle fibers or rimmed vacuoles, performed with a 90%
sensitivity and 96% specificity among 371 patients.43
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Pathomechanisms in IBM
Histopathological hallmarks of IBM muscle feature both
myodegenerative multi-protein aggregates as well as endo-
mysial lymphocytic infiltrates.2–4 Several lines of evidence
suggest that inflammatory mechanisms precede myode-
generation,8 but so far a precise answer and sound evi-
dence is lacking as discussed below in detail. Currently, it
remains unresolved and controversially discussed if the
inflammatory changes observed in IBM muscle are a
direct result of primary myodegeneration or if protein
aggregation is secondary to initial inflammatory events.
The solution of this conundrum is key to identify an
appropriate remedy for this debilitating disease.
Immunopathomechanisms in IBM
Endomysial lymphocytic infiltrations in IBM muscle are
usually found at perivascular sites and appear scattered.
Similar to PM, the mononuclear infiltrates in IBM pre-
dominantly consist of CD8+ cytotoxic T cells (CTLs) sur-
rounding nonnecrotic muscle fibers. More than 30% of
all invading cells and around 50% of invading CD8+ T
cells depict activation marker positivity.44 Unlike in
healthy individuals, scattered clusters of nonnecrotic mus-
cle fibers ectopically express MHC class I molecules in a
moderate to strong degree on their surface3,45 and infil-
trating CD8+ T cells form close contacts with these MHC
class I expressing fibers (Fig. 1). While a considerable
amount of muscle fibers with cytoplasmic abnormalities
(such as lined vacuoles) do not express MHC class I,
regenerating muscle fibers in IBM muscle do show sar-
colemmal expression of this molecule.45 Although macro-
phages constitute only a minor fraction of the
mononuclear infiltrates invading nonnecrotic muscle
fibers, they account for up to 80% of the infiltrates sur-
rounding necrotic fibers.44 Distinct from DM but consis-
tent with lymphocytic infiltrates observed in PM, muscle-
invading CD8+ T cells stain positive for pore-forming and
cytolytic molecules such as perforin, granzyme A, and
granulysin.46–48 It has been demonstrated that perforin-
polarization within endomysial CD8+ T cells occurs
toward target myofibers indicative of immunosynapse for-
mation and arguing strongly for a possible recognition of
specific antigens presented via MHC class I expressing
myofibers.49 In line with this, muscle fibers in IBM
patients express co-stimulatory molecules such as ICOS-L,
CD276, and BB1 on their surface.48,50,51
Immunohistochemical and RT-PCR analyses revealed
preferential usage of certain CD8+ T cell receptor (TCR)
variable segments in endomysial infiltrates compared to
peripheral CD8+ T cell-TCR profiles in IBM patients.52,53
Although conclusive proof is still lacking, this myo-
peripheral discrepancy of TCR restriction suggests that
CD8+ T cells patrol the muscle in a stochastical manner
and only upon recognition of their cognate antigen clon-
ally expand in situ. In line with this, endomysial T cells
depict expression of proliferation marker Ki-67 suggestive
of a pervasive antigen-driven response within the muscle
compartment.54 However, specific recruitment to the
muscle compartment remains a possibility. Using the
combination of RT-PCR, immunohistochemistry and
TCR Vb chain CDR3 spectratyping in three sequential
muscle biopsies of three IBM patients, Amemiya et al.
found clonal persistence of CD8+ T cells in subsequent
muscle biopsies. This is supportive of earlier studies and
suggests that IBM might be maintained by a continuous
antigen-driven T cell response.55,56 Additionally, a more
recent CDR3 spectratyping study of CD8+ T cell-TCR Vb
chains in 12 IBM patients identified Vb 9, 10, 11, 16, 18,
23, and 24 as subfamilies with the strongest degree in
myo-restriction. Indicative of determinant spreading, fol-
low-up muscle biopsies (after 12 months) confirmed per-
sisting CD8+ T cell clonality, while the pattern of
expanded Vb subfamilies had changed.57
Viruses
By analogy to numerous autoimmune diseases, a viral
contribution to the etiology of IBM has been discussed
for as long as the condition has been identified.58,59 Pre-
sently, it is not ultimately clear by which exact mecha-
nism(s) viruses may trigger autoimmunity. Host-inherent
anti-viral responses comprise a meticulously regulated
mounting of the immune system. Erroneous and faulty
progression of such antiviral responses may lead to subse-
quent break-down of self-tolerance with concomitant epi-
tope spreading and recognition of auto-antigens60
(Fig. 2). Other potential virus-mediated mechanisms
include bystander activation and immortalization of low-
affinity autoaggressive effector cells due to unphysiological
exposure and subsequent presentation of self-antigens in
the context of a strong antiviral response.60 Despite con-
siderable effort, so far no virus could be isolated and
amplified from affected muscle tissue of IBM patients and
no conclusive evidence for a viral trigger of this myopathy
exists.3,61 However, an association with human immuno-
deficiency virus (HIV)62 and human T lymphotropic virus
(HTLV)63,64 seropositivity has been clearly demonstrated
and in the case of HIV as many as 10% of infiltrating
CD8+ T cells showed specificity for human leukocyte anti-
gen-A* 0201-HIV-gag. Worthy of note, in both cases
HIV- and HTLV-derived viral antigens could not be
detected in muscle fibers but exclusively on endomysial
macrophages.62,63 Furthermore, an association between
hepatitis C virus (HCV) infection and IBM was recently
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reported in a Japanese case–control study that included
114 IBM and 44 PM patients.65 While the frequency of
PM patients that also carried anti-HCV antibodies was
comparable to the general population that of IBM
patients was significantly increased.65 However, these data
need to be interpreted carefully and it appears to be unli-
kely that HCV is a key determinant in the development if
IBM. The increasing incidence of IBM in Japan is in
strong contrast to the decreasing incidence in HCV infec-
tions.66–68 Moreover, countries with relatively high inci-
dence rates of HCV infections belong to the regions that
are stricken the least by IBM.26,30,61,69–71 It is conceivable
that nonpersistent contact with a pathogen suffices to
trigger autoimmunity.72 At this point, a viral contribution
to the etiopathogenesis of IBM cannot be ruled out, yet
more conclusive evidence is clearly needed.
CD8+ T cells
With regards to differentiation, surface marker expression
and functionality, the CD8+ T cell compartment displays
considerable heterogenicity. Short-telomer-bearing
CD8+CD28 T cells are thought to comprise a highly dif-
ferentiated oligoclonal subset arising from chronic antigen
exposure as hypothesized for IBM19,49,73–77 and several
autoimmune conditions are accompanied by increased
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Figure 1. Scheme of the pathological changes in inclusion body myositis compared to healthy muscle. Mainly nonnecrotic, MHC class
I-expressing myofibers are surrounded by invading CD8+CD28 T cells, which is the predominant immune subset in the endomysial infiltrates.
These CD8+CD28 T cells form immunological synapses with MHC class I bearing myofibers, contain cytolytic proteins, release proinflammatory
cytokines, and express costimulatory molecules corresponding to complementary molecules on the surface of myofibers. Additionally, myofibers
themselves are immunologically active via releasing myokines. Albeit they are found less frequently, also CD4+ T cells and CD138+ plasma cells
are present in the endomysium and may contribute to the myoinflammatory environment. Degenerating myofibers are mainly surrounded by
macrophages and contain APP-derived b-amyloid and phosphorylated tau. If the disruption of proteostasis by virtue of impaired macroautophagy
and defective proteasomal degradation is an upstream event in the pathomechanism of IBM or if it follows the increasing aggregation of aberrant
proteins, remains a matter of debate.
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frequencies of CD8+CD28 T cells.78–80 Furthermore,
muscle-infiltrating CD8+ T cells in patients suffering from
PM and DM have been reported to be mainly CD28.81
Two recent studies showed that frequencies of highly
cytotoxic CD8+CD28 T cells in inflamed muscle and in
peripheral blood of IBM patients are significantly
increased and their capability to secrete IFNc was superior
compared to healthy controls.82,83 CD8+CD28 T cells
are devoid of costimulatory interaction between CD80:
CD28, however, it is reported that CD8+CD28 T cells
after CD3 ligation in turn upregulate alternative costimu-
latory molecules such as inducible costimulator (ICOS),
CD134 and CD13784 which could facilitate T cell: muscle
fiber interaction and is in keeping with the observed
upregulation of ICOS-L on muscle fibers during IBM.48
Aside from lacking CD28-expression, expression of the
terminally sulfated glycan carbohydrate CD57 is generally
regarded as a marker for terminal differentiation and clo-
nal exhaustion on CD8+ T cells and this T cell subset is
commonly oligoclonally expanded during conditions of
chronic immune activation.85–87 CD8+CD57+ T cell fre-
quencies are especially increased in the elderly, they have
strong cytotoxic potential, high expression of adhesion
molecules, strong migratory potential toward nonlym-
phoid organs and – indicative of a cytotoxic effector
memory phenotype – they depict expression of CX3CR1.
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Figure 2. Schematic overview of a possible crosstalk between key pathological mechanisms during IBM. Genetic predisposition, aging, and
exposure to a yet unidentified viral trigger may each individually or in combination lead to breakdown of immune tolerance with subsequent
activation of the adaptive immune system. Invasion of myoantigen-specific T cells into the endomysium could establish and maintain a
pro-inflammatory environment in the muscle. Upregulation of MHC class I and II molecules on myofibers and release of myokines in response to
inflammation may serve as a feedback loop that helps to perpetuate disease. Disturbed proteostasis may result in response to specific
pro-inflammatory mediators. Conversely, it is argued, that a primary event within myofibers leads to degenerative changes that entail
inflammation as a secondary event, yet evidence for this latter scenario is lacking.
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It is believed that CD8+CD57+ T cells are highly differen-
tiated antigen-driven effector cells in a state of replicative
senescence with limited capacities to proliferate.88–92
Recent reports, however, suggest that these CD8+CD57+
CD28 T cells might comprise a rather heterogeneous
group of highly antigen-experienced cells that, depending
on the immunobiological context and stimuli, differ in
their susceptibility to apoptosis and their capability to
proliferate and expand.84,93–95
During T cell-large granular lymphocytic leukemia (T-
LGL leukemia) clonally expanded large granular
CD8+CD57+ CTLs can be found in peripheral blood,
spleen and bone marrow.96 Interestingly, a recent study
describes a previously undiscovered association between
IBM and T-LGL leukemia.97 T-LGL leukemia is a rare con-
dition within the spectrum of lymphoproliferative disor-
ders on the interface between neoplasia and extensive
antigen-driven CTL response and is frequently associated
with autoimmune disorders.98–100 According to this new
study, the clinical criteria for an expanded LGL population
in association to an autoimmune disorder101 were met in
more than half of the 38 investigated IBM patients. Green-
berg and colleagues controversially argue that, at least in
some cases of IBM, an initial autoimmune process might
transform into a neoplasia-like condition with extensive
clonal expansion of large granular CTLs resembling those
of T-LGL leukemia.97 This is especially intriguing in light
of the fact that IBM is refractory to common immunother-
apies. Frequently, this lack of efficacy in targeting the
immune system has given rise to the assumption that IBM
might be primarily a myodegenerative disorder and the
inflammatory component little more than an etiopatho-
genetic epiphenomenon.7,102,103 Although further investi-
gation into the matter is needed, this recent study offers a
different narrative, which would have substantial implica-
tions toward both the diagnosis and therapy of IBM.104
Other infiltrating immune cells
Aside from the previously described cytotoxic CD8+ T
cells, inflammatory infiltrates in IBM additionally harbor
myeloid cells,105 plasma cells,106 and CD4+ T
cells.44,48,82,83,107,108 Early studies have previously revealed
that the antigen-presenting properties of human myocytes
exceed the mere bearing of MHC class I molecules. In
fact, muscle fibers can be categorized as facultative anti-
gen-presenting cells, that in a proinflammatory milieu can
upregulate MHC class II molecules, express intercellular
adhesion molecule (ICAM)-1 and ICOS ligand (ICOS-
L).108–110 In line with this, MHC class II expressing mus-
cle fibers are found in IBM.108 In fact, up to 66.7% of
muscle fibers in IBM show high positivity for MHC class
II as opposed to lower counts in other IIMs (PM: 23.7%;
DM: 20%).111 Interestingly, microdissection studies
revealed that HLA-DR, HLA-DB, and CIITA are predom-
inantly upregulated in infiltrated but not in healthy
appearing muscle fibers.112 Comparable to their CD8+
counterpart, CD4+ T cells in IBM are mostly devoid of
CD28-expression, display a striking TCR Vb restriction,
and are expanded in the peripheral blood as well as in
inflamed muscle tissue.83 Similar to CTLs, they depict a
strong proinflammatory phenotype and cytotoxic proper-
ties which might be executed toward MHC class II-bear-
ing muscle fibers.83 Additionally, local presentation of
antigen via professional antigen presenting cells (APCs)
or MHC class II bearing muscle fibers has been sug-
gested.105,108 The pathological role of CD4+CD28 T cells
during IBM, therefore, might have been underappreciated
so far.
Tregs
FOXP3+CD4+ T regulatory cells (Tregs) constitute a
unique lymphocyte subset that holds the capacity to
control and limit immune responses mounted against
self- and foreign antigens in order to retain immune
homeostasis and self-tolerance.113,114 It has become evi-
dent that distinct tissue-specific Treg populations with
unique phenotypical and functional properties exist. In
skeletal muscle, they arise from a small pool of resident
Tregs and strongly accumulate following muscle dam-
age.115,116 Under the control of interleukin (IL)-33, these
myophil Tregs execute essential functions in promoting
and orchestrating local regeneration upon muscle
injury.117,118 Importantly, they are significantly dimin-
ished in aged mice, leading to insufficient muscle repair
upon injury.118 A critical role for Tregs during myositis
had already been postulated in an experimental autoim-
mune myositis model during which antibody-mediated
depletion of Tregs leads to significant increase of the
histopathological disease score and a more diffuse muscle
inflammation pattern.119 On the contrary, in vitro
expanded adoptively transferred polyclonal Tregs are able
to decrease the severity in this model. These findings are
extended by a study that, employing a new model, adop-
tively transferred FOXP3/synaptotagmin VII double
mutant-derived lymphocytes into RAG-1/ mice
together with muscle antigens. This entails strong myositis
reflected by myofiber infiltrating CD4+ and CD8+ T cells
and macrophages. Coadministration of functional Tregs
fully protects animals from developing myositis.120 Fur-
thermore, the capacity of Tregs to dampen CD8+ T cell
cytotoxicity directed against human myoblasts has been
confirmed in vitro121 and immunohistochemical studies
in IBM muscle revealed presence of Tregs in close spatial
association to other infiltrating mononuclear cells. The
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amount of Tregs positively correlated with the amount of
total CD3+ cells. However, these results are not specific
for IBM but could be obtained in PM and DM muscle as
well.121 A more recent report shows a significant decrease
in circulating Tregs in IBM patients compared to non-
myositic controls.82 Functionality of the remainder of
peripheral Tregs with regard to proliferation-suppression
of autologous T cells, however, was unaffected.82 This
study also confirmed the previous finding that Tregs are
indeed present in inflamed muscle of IBM patients.82 To
which degree this report is specific to IBM or if similar
results were to be obtained in other inflammatory myopa-
thies remains to be investigated. The physiological role of
muscle-resident Tregs and their contribution during
myositis has only begun to unravel. It becomes apparent
that few studies so far addressed the presence and subcat-
egorization of CD4+ T cells, including Tregs (which con-
stitute up to 60% of CD4+ T cells in muscle upon
injury116), in muscle infiltrates of IBM. Such work could
help to better understand the role of these cells.
B cells, plasma cells, and autoantibodies
Despite the often-proclaimed predominant role of CD8+
T cells in IBM, several reports suggest an underrated
humoral component in the immunopathology of inflam-
matory myopathies. Sera from IBM patients contain
increased amounts of muscle antigen-reactive monoclonal
antibodies122 and although CD20+ B cells are scarce, sub-
stantial numbers of transcriptionally active CD138+
plasma cells can be detected in inflamed muscle of IBM
patients.106 Immunoglobulin heavy chain gene transcript
analyses in IBM, PM, and DM revealed that these cells
undergo isotype switching, oligoclonal expansion and
somatic hypermutation which suggests local affinity matu-
ration of antibodies,123 a process that usually occurs in
germinal centers under the aid of follicular dendritic cells
(fDCs) and follicular B helper T cells.124–126 In fact, an
early study characterized nodular lymphocytic accumula-
tions in inflamed muscle and found microanatomical orga-
nization patterns as well as adhesion molecule expression
reminiscent of those in secondary lymphoid organs.127
Others, however, have reported that these nodular accu-
mulations lack B cell follicles and presence of DRC+ fDCs
characteristic for lymphoid germinal centers.128
B cell maturation is highly dependent on bidirectional
interactions with cognate CD4+ T cells.124–126 Amongst
others, ICOS:B7RP-1 ligation is essential for the successful
execution of this crosstalk.129 In line with this,
ICOS+CD4+ T cells have been reported to be present in
IBM infiltrates.48 B cell activating factor of the TNF
superfamily (Baff) is a cytokine crucial for B cell survival
and has been implicated in autoantibody formation in
patients suffering from autoimmune diseases.130 Serum
levels of Baff are elevated in some patients suffering from
IIMs including IBM patients.131 Furthermore, Baff tran-
scripts are markedly increased in muscle tissue from IIM
patients compared to nonmyositic controls
(IBM>PM>DM).128 However, serum Baff levels were
highest in IIM patients that also had detectable levels of
anti-histidyl-tRNA-synthetase antibody Jo-1, an autoanti-
body that is extremely rare in IBM.132–134 Additionally,
Baff serum levels seem to positively correlate with serum
CK levels, which can be normal to only moderately ele-
vated in IBM.131
The presence of specific autoantibodies is not only rele-
vant with regard to possible therapeutic options but has
immediate implications for diagnosis. Autoantibodies
associated with myositis have been identified in more
than half of the patients suffering from myositis.3,135,136
In 2011, a previously undetected circulating antibody
against a muscle-derived protein was found in 52% of
IBM patients (13/25) but was absent in control individu-
als (PM, DM, healthy volunteers).137 Shortly thereafter,
the group and others identified the target of these anti-
bodies to be cytosolic 50-nucleotidase 1A (the antibody is
now commonly referred to as anti-cN1A antibody).138,139
Moderate reactivity of anti-cN1A antibodies was reported
to be 70% sensitive and 92% specific for the diagnosis of
IBM.136 Another study reported similar numbers, detect-
ing anti-cN1A antibodies in 61% of IBM patients but on
the other hand also in 5% of PM, 23% of Sj€ogren’s syn-
drome patients (SS), and 14% of systemic lupus erythe-
matosus (SLE) patients, even in absence of any muscular
symptoms.140 In a subsequent report however, the fre-
quency of seropositive IBM patients was only 34.8% (24/
69).141 Circulating anti-cN1A antibodies may aid in dis-
tinguishing IBM (37%) from PM and DM (<5%), how-
ever, the picture becomes less clear when acknowledging
that these antibodies are also detected in autoimmune
conditions such as SS (36%) and SLE (20%).142 The pres-
ence of anti-cN1A antibodies is neither associated with
gender nor malignancy and appears to be independent of
specific HLA-DR alleles.141 Two recent reports also found
anti-cN1A antibodies in 33% (102/311)143 and 35.8%
(24/67)144 of IBM patients, respectively. The anti-cN1A
positive IBM patients showed a higher adjusted mortality
risk and depicted more cytochrome oxidase deficient
muscle fibers as compared to sero-negative patients.143
Moreover, passive immunization with purified IgG frac-
tions derived from either anti-cN1A-positive or anti-
cN1A-negative IBM patients in in vitro and in vivo mod-
els, led to myodegenerative changes (such as p62 protein
aggregation), resembling those observed in IBM mus-
cle.144 Whether pathogenicity is directly transferred via
anti-cN1A antibodies or if presence of these
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autoantibodies is simply indicative of other, yet unidenti-
fied mechanisms is so far unclear.145
Taken together, the above-mentioned findings argue
for B cell activation with subsequent production of
autoantibodies against muscle epitopes in IBM. However,
the pathogenetic role of B cells, their specificity and rele-
vance needs further investigation.6
Inflammatory mediators – cytokines, chemokines,
and myokines
Signal peptides secreted by invading leukocytes and resi-
dent myofibers alike are an integral part of the inflamma-
tory milieu in muscle and are believed to directly
contribute to the pathology of IBM via induction of sur-
face molecules (on myofibers and invading leukocytes),
chemotaxis of myoaggressive immune cells and subse-
quent muscle injury. The interplay of soluble factors and
expression patterns of their respective surface receptors is
complex and dynamic in its nature and a plethora of key
suspects have been suggested.146
An early immunocytochemistry study that evaluated
expression of inflammatory mediators in myositis, found
predominant presence of IL-1a (in endothelial cells), IL-
1b and TGF-b (both in inflammatory cells), albeit no
apparent difference in the expression pattern was
observed between DM, PM and IBM.147 Similarly, De
Bleeker and colleagues detected TNF-a in macrophages,
endothelial cells, and central myonuclei in IBM, DM,
and PM muscle but not in that of nonmyositic con-
trols.148 Chronic administration of TNF-a via osmotic
minipumps has shown to be already sufficient to attract
neutrophils and macrophages to the muscle compart-
ment.149 A more recent study found mRNA levels of
GM-CSF, IL-4, IL-10, IL-12, IL-13, IL-23, IL-1b and
TNF-a to be significantly increased in IBM muscle com-
pared to healthy controls. Although this was also true for
PM muscle, DM muscle did not present with increased
levels of these cytokines and TNF-a showed the highest
values in IBM patients.150
Thrombospondin-1 (TSP-1) has been reported to func-
tion as a chemoattractant for leukocytes to sites of
inflammation and interaction with its ligands activates
and perpetuates autoaggressive T cell expansion.151,152
Furthermore, expression of TSP-1 and its binding part-
ners CD36 and CD47 is upregulated on mRNA and pro-
tein level in IBM153 and TNF-a can induce TSP-1 and
CD47 expression on human myoblasts in vitro.153
A crucial role for IFNc in the pathoetiology of IBM has
been proposed as well.136 During IBM, muscle fibers
ubiquitously express MHC class I on their surface and to
a higher degree than DM or PM muscle.154 However, not
all MHC class I bearing myofibers depict presence of
immune infiltrates and although MHC class I expression
seems to sustain CD8+ T cell myoinfiltration in the case
of IBM, MHC class I expression by itself seems not to be
sufficient to entail infiltration of cytotoxic T cells (as
demonstrated during DM, where muscle fibers express
MHC class I but no CD8+ T cell infiltrates can be
detected).45,155 Ivanidze et al. reported segmental upregu-
lation of IFNGR2, exclusively on attacked MHC class I-
expressing myofibers vs. MHC class I bearing myofibers
that did not have infiltrates (nonattacked myofibers). The
expression of IFNGR2 positively correlated with the
amount of infiltrating CD8+ T cells.112
This strongly argues for MHC class I upregulation
upstream and independent of IFNc signaling during IBM.
It is possible that, following this ubiquitous expression of
MHC class I on myofibers upon a so far unknown trig-
ger, CD8+ T cells might recognize cognate antigen in a
stochastical manner, become activated, expand and secrete
proinflammatory cytokines which, in turn, may induce
IFNGR expression and perpetuate susceptibility toward
further myocytotoxicity.112 In line with this, CD8+CD28
T cells found in the peripheral blood of IBM patients are
more prone to produce IFNc and IFNc-inducable
chemoattractant mediators such as CXCL-9, CXCL-10
and IL-12 are increased in serum of IBM patients com-
pared to nonmyositic controls.82 Aside from infiltrating
leukocytes, myofibers themselves might also actively par-
ticipate in secreting proinflammatory mediators. Upregu-
lated mRNA expression levels of CXCL-9 and CXCL-10
in muscle biopsies of IBM patients had been reported
before and the same study demonstrated synthesis of
CXCL-9 and CXCL-10 by human muscle fibers after IFNc
incubation in vitro.156 However, as with other cytokines
discussed previously, CXCL-9 and CXCL-10 regulation is
confirmed for other IIMs as well and these changes seem
to reflect a general inflammatory milieu and maintenance
of such within the muscle compartment.157
One conceivable alternative mechanism responsible for
initial upregulation of MHC class I (upstream of IFNc sig-
nalling) includes viral genesis (as discussed above)62–64,158
or other proinflammatory cytokines like TNF-a and IL-
1b.112,159 Interestingly, in addition to IFNGR2 expression,
transcripts of RANTES and Stat3 are reported to be
increased in attacked myofibers vs. nonattacked myofibers
as well.112 RANTES is produced in response to TNF-a and
synergistic effects between TNF-a and IFNc with regards
to RANTES synthesis are reported.160,161 Additionally,
pro-inflammatory cytokines like IL-1b and, in particular,
TNF-a might hamper myoregeneration in IBM (and other
IIMs) by suppressing myogenic microRNAs such as miR-
1, miR-133a and miR-133b.150 TNF-like weak inducer of
apoptosis (TWEAK) is a recently described member of the
TNF superfamily. The proinflammatory cytokine signals
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through binding to its receptor Fn14 and activates NFjb
in a TGFb-activated kinase 1-(TAK1-) dependent man-
ner.162 TWEAK is expressed in a wide variety of cell types
including monocytes and macrophages, dendritic cells and
T cells163–167 and its implications in controlling muscle tis-
sue repair and regeneration have reaffirmed its role as a
key regulator of myogenesis.164,168 As opposed to DM, PM
and healthy mesoangioblasts, IBM mesoangioblasts fail to
fully differentiate into skeletal myotubes.169 A recent study
found increased TWEAK-Fn14-expression in IBM muscle
compared to DM and PM muscle. Moreover, culture
media from IBM-derived differentiating mesoangioblasts
show significantly higher levels of TWEAK as compared to
nonmyositic or DM controls and IBM-derived mesoangio-
blasts depict higher Fn14-expression than those derived
from other IIMs.170 During chronic inflammatory condi-
tions, TWEAK has been shown to mediate proliferation of
precursor cells while prohibiting their terminal differentia-
tion.171 Furthermore, a critical role for TWEAK/Fn14 in
fostering muscle atrophy has been proposed.172,173 There-
fore, disbalance of the TWEAK/Fn14 axis may, similarly to
what has been reported for TNF-a and IL-1b, block myo-
genic differentiation through NFjb-signalling174,175 and,
additionally, promote progressive muscle wasting and
atrophy during IBM. Interestingly, in a colitis model,
TWEAK, IL-13, and TNF-a act in concert and synergisti-
cally promote intestinal epithelial cell injury and induction
of fibroblast proliferation.176,177 Although a possible role
for IL-13 in the pathomechanism of IBM has not been
addressed thus far, mRNA levels in muscle derived from
nonmyositic controls and different IIMs depicted the
highest and most consistent levels of IL-13 in IBM sam-
ples.150
Finally, potential regulatory roles in the pathomecha-
nism of IIM have been ascribed to IL-17A and IL-
15.178,179 However, most studies have so far focused on
PM and DM and little data are currently available in
IBM. Given the similarities in the inflammatory muscle
milieu, especially that of PM, IL-15 and IL-17A should be
further investigated for their involvement in IBM.
The differential interaction of selected cytokines with
degenerative pathomechanisms during IBM will be dis-
cussed further below.
Degenerative pathomechanisms in IBM
Aside from the previously discussed inflammatory com-
ponent of IBM, its pathoetiology includes distinct myode-
generative changes including, but not limited to,
vacuolization, abnormal posttranslational modifications of
proteins with subsequent congophilic misfolded multi-
protein aggregates and dysfunctional mitochondrial
activity.7,103 The observation that IBM behaves largely
refractory to anti-inflammatory treatment gave rise to the
proposition that inflammatory myofiber infiltrates are lar-
gely an epiphenomenon to age-related primary myode-
generative events similar to neurodegenerative disorders
such as Alzheimer’s disease (AD) and Parkinson’s disease
(PD).7,103 In the following section, we will discuss the
degenerative changes observed in IBM muscle and evalu-
ate the possible pathomechanistic interrelationship with
inflammatory processes.
Amyloid-b, a-Synuclein, Presenilin, Tau
Detection of intracellular accumulation of amyloid pre-
cursor protein (APP)-derived amyloid-b (Ab) peptides as
congophilic inclusions was amongst the first evidence for
defective myoproteostasis in IBM muscle.180–182 Ab is
usually generated as an either 40 or 42 amino acid-long
peptide. The more hydrophobic 42 amino acid long iso-
form exhibits a stronger tendency to self-associate into
insoluble fibrils, oligomerize and cluster into aggregates
than Ab1-40.
183–185 It is therefore considered to be more
cytotoxic and the predominant isoform to be accumu-
lated as oligomers in IBM muscle.186,187 Congophilic Ab
is detected in up to 70% of IBM muscle fibers and mostly
found in nonvacuolated areas.188 Ab peptides are gener-
ated via the sequential cleavage of the transmembrane gly-
coprotein APP by the protease b-site of the APP cleaving
enzyme 1 (BACE1) and the c-secretase complex.189–191
Components of the sequential cleavage machinery of
APP, such as BACE1, are upregulated in IBM mus-
cle.192,193 Recently, a c-secretase activating protein (GSAP)
has been characterized, which selectively mediates Ab gen-
eration via facilitating the interaction between c-secretase
complex members and APP-CTF.194 IBM muscle fibers
depict increased protein and mRNA expression of GSAP
in comparison to nonmyositic controls.193 Consequently,
the members of the c-secretase complex that catalyzes the
final step of the Ab generation, such as nicastrin, prese-
nilin-1 (PS-1) and presenilin enhancer 2 are increased on
protein and mRNA level in IBM muscle.193 Phosphoryla-
tion of APP by glycogen synthase kinase 3b (GSK3b)
facilitates increased generation of cytotoxic Ab.195,196 In
line with these findings, GSK3b is activated and APP is
found to be highly phosphorylated in IBM muscle.197
One study evaluated plasma levels of Ab in IBM
patients compared to myositic and nonmyositic controls
and although Ab plasma levels were increased in IBM
compared to PM, levels were also elevated in DM disqual-
ifying the assay as an appropriate diagnostic tool.198 A
more recent report, however, found that plasma levels of
BACE1, PS-1 and soluble APP are increased in IBM
patients compared to healthy controls and patients diag-
nosed with PM and DM.199
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Aside from extracellular amyloid plaques, also intraneu-
ronal neurofibrillary tangles mainly comprised of the
microtubule-associated protein tau, are a morphological
feature of AD brains.200–202 There is evidence that Ab
partly executes its cytotoxicity upstream of tau hyper-
phosphorylation and subsequent self-assembly.203,204
Aspects of Ab cytotoxicity are tau-dependent, indicating a
reciprocal, self-enhancing component during the interac-
tion of the two.205 Cytoplasmic hyperphosphorylated tau
tangles in AD brains consist predominantly of 15–21 nm
long paired helical filaments (PHF).201 Similarly, in IBM
muscle, accumulations of hyperphosphorylated tau-con-
taining PHF are observed and kinases such as extracellular
signal-regulated kinase (ERK) or GSK3b, which have been
reported to phosphorylate tau, are increased and colocal-
ized with tau in IBM muscle fibers.206–210
a-Synuclein, another aberrant protein that is present
as insoluble cytoplasmic aggregates in neurodegenerative
brain disorders also abnormally accumulates in IBM mus-
cle fibers.211–215 Expression and toxicity of the small pro-
tein is increased under conditions of oxidative stress but
is negatively regulated by the activity of heat shock pro-
teins.216–218 Interestingly, a-synuclein has been reported
to facilitate phosphorylation of tau by the above men-
tioned kinase GSK3b.219
In addition to Ab, hyperphosphorylated tau and a-
synuclein also ApoE,220,221 p62/SQSTM1222 and prion
protein223–225 are found to be aggregated in IBM muscle
fibers, all indicative of protein dyshomeostasis being a
distinctive feature of IBM. In support of this, a recent
study found that treatment with arimoclomol, a coin-
ducer of heat shock responses, significantly ameliorated
IBM-like phenotype in vitro and in vivo and appeared to
be safe in a proof-of-concept study with IBM patients.226
The clinical efficacy of arimoclomol is currently tested in
a clinical trial (NCT02753530).
Faulty protein disposal: the proteasome &
autophagy
Although there is now a plethora of convincing evidence
for severe defects in myoproteostasis, the individual speci-
ficity of the aforementioned aggregated proteins in IBM
pathology remains to be further evaluated. The pathoetiol-
ogy of IBM appears to follow a dynamic pattern and a
given muscle biopsy at a given stage of the disease may
greatly differ from those taken at different time points or
even locations. In fact, the paradox is not limited to IBM.
In AD, which regularly serves skeptics as a paramount
example for a bona fide amyloid-disorder, more than one-
third of ApoE noncarriers that clinically present with mild
to moderate cognitive deficit, do not show significant cere-
bral amyloidosis in positron emission tomography.227–229
The underlying causative event that promotes and
propagates self-aggregation of aberrant proteins in IBM
myofibers has yet to be elucidated. A delicately regulated
surveillance of protein turnover is especially crucial in
postmitotic cells such as neurons and myocytes.230–234
Eukaryotic cells employ two predominant molecular sys-
tems to keep a tight balance between translation and
degradation of cellular proteins, namely the proteasomal
system and autophagy.235–237 Dysfunction in either of
these two proteolytic systems, and subsequent imbalance
of protein homeostasis, is one of nine defining character-
istics of cellular aging.238 However, severity, time of onset,
and acceleration of these pathomechanisms determine to
which degree these changes will meet the pathological
spectrum.235,237,238
The proteasome
In the ubiquitin-proteasomal system (UPS), sequentially
polyubiquitylated proteins are targeted toward the barrel-
shaped multipartite 26S proteasome which executes cas-
pase-like, trypsin-like, and chymotrypsin-like proteolytic
activities located on its b-subunits (b1, b2, and b5,
respectively).239 The proteasomal system is tightly con-
trolled by regulatory molecules and executes ubiquitin-
dependent and -independent proteolytic degradation.240
Polyubiquitination-independent recognition and subse-
quent degradation of oxidized substrates by the core par-
ticle 20S proteasome is especially relevant in the context
of aging cells.235,241
Fratta et al. have reported that the 26S proteasome co-
stains with Ab, phosphorylated tau, ubiquitin, and heat
shock protein 70 (Hsp70) in muscle biopsies from IBM
patients.242 While protein expression of proteasomal sub-
units 19S, 20Sa, and 20Sb is greatly increased in IBM
muscle compared to age-matched controls, proteolytic
activity of the proteasomal machinery is significantly
impaired in IBM muscle. In accordance with this, inhibi-
tion of the proteasome in human myofibers in vitro leads
to formation of aberrant multiprotein aggregates.242
Particularly cells of the hematopoietic system harbor a
unique form of the proteasome, termed the immunopro-
teasome, in which the catalytic b subunits b1, b2, b5 have
been replaced by b1i, b2i, and b5i resulting in increased
enzymatic cleavage following hydrophobic residues and
decreased cleavage following acidic residues, respec-
tively.243–245 Exchange of constitutive proteasome sub-
units with immunoproteasome sub-units distinctively
shapes the pool of MHC class I ligands and can be facili-
tated via exposure to proinflammatory cytokines like
IFNc and TNF-a.243,244 A recent study found that the
immunoproteasome sub-units b1i and b5i are upregu-
lated and colocalized with MHC class I molecules in IBM
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muscle.246 In vitro experiments show that exposure to
TNF-a and IFNc increases replacement toward immuno-
proteasomal sub-units in primary human myoblasts and
the selective inhibition of proteasomal subunit b5i in
myoblasts results in increased expression of TNF-a and
IFNc-dependent myokines like IL-1b, IL-6, CXCL-9, and
CXCL-10.246 However, these results were also obtained in
other IIM such as DM and immune-mediated necrotizing
myopathy, indicating a downstream effect of preceding
myoinflammatory events. It remains unclear if proteaso-
mal dysfunction is a primary event in IBM pathology, or
if soluble intermediates of aggregation-prone proteins
facilitate proteasomal inhibition.
Autophagy
Autophagy comprises a set of intracellular catabolic path-
ways that degrade cytoplasmic content by means of the
lysosomal system.247,248 While occupying pivotal roles
during host defense against microbes, induction of toler-
ance, antigen-presentation, and tissue differentiation, a
key function of autophagy pathways is to maintain a
well-balanced proteostasis and provision of metabolic
building blocks and energy sources in response to nutri-
ent deprivation and other cellular stressors248–252 As
opposed to the proteasomal system, autophagy, in addi-
tion to removing aberrant proteins, aids in the removal
of defective or excess mitochondria, lysosomes and per-
oxisomes and keeps, thereby, homeostasis on the level of
macromolecules and whole organelles alike.253–256 Conse-
quently, defective autophagy pathways have been ascribed
a pathological role in degenerative diseases of the
brain236,237,257 and emerging evidence implicates auto-
phagy in the pathoetiology of IBM. Initial hints about
malregulated autophagy in IBM were introduced in an
early study in 1980.258 However, it took another 24 years
for evidence that members of the autophagy machinery
(Atg5 and Atg12) are upregulated on mRNA level in IBM
muscle as compared to healthy and amyotrophic lateral
sclerosis muscle.259 We demonstrated that accumulated
APP and its proteolytic fragment Ab in skeletal muscel
fibers are targeted for lysosomal degradation via
macroautophagy.260 We observed APP/Ab-containing
autophagosomes at increased frequency in muscle fibers
of IBM muscle biopsies, but not in nonmyopathic muscle
or nonvacuolated myopathic controls. Moreover, Ab-
containing autophagosomes were almost exclusively
observed in degenerating muscle fibers of the type II (fast-
twitching) and in part associated with overexpression of
MHC class I and II on myofibers and invasion by CD4+
and CD8+ cells.260 A more recent immunohistochemistry
study reports overexpression of the autophagy proteins
ATG5, microtubule-associated protein light chain 3
(LC3) and Beclin-1 in IBM muscle biopsies. Interestingly,
lymphocytic infiltrates were predominantly found sur-
rounding Beclin-1+ myofibers.261 Recently, components
of chaperone-mediated autophagy were identified to be
increased in IBM as well.262 G€uttsches et al. identified an
overrepresentation of rare missense coding variants of an
autophagic adaptor protein facilitating autophagosome
trafficking, FYCO1, in IBM patients and suggested that a
failure in autophagosome/endosome trafficking may
underlie IBM pathogenesis.263 In addition to FYCO1,
missense pathogenic variants responsible for autophago-
some maturation and degradation (VCP and p62/
SQSTM1) have been found in patients with IBM.264,265
We could previously show that autophagy is constitu-
tively active in human myocytes and can be upregulated
via the proinflammatory cytokines TNF-a108 or IFNc
together with IL-1b.266 Interestingly, composite exposure
to TNF-a and IFNc leads to significant autophagy-depen-
dent translocation of intracellular MHC class II to the
cell surface in myocytes and more than 40% of muscle
fibers in IBM that costain for autophagosomes and MHC
class II have contact to CD4+ and CD8+ infiltrating T
cells.108 Dengjel and colleagues reported that upregulation
of autophagic activity, by means of altered lysosomal
processing, significantly increases the fraction of intracel-
lular source protein-derived peptides presented on MHC
class II.267 These findings suggest that the proinflamma-
tory environment in IBM muscle promotes induction of
autophagy in myofibers and subsequently enhances sur-
face MHC class II, thereby maintaining CD4+ T cell infil-
trates via the presentation of yet unknown self-peptides.
Intracellular antigen presentation via MHC class I mole-
cules is also regulated by the autophagy machinery,
because autophagy-related proteins enhance MHC class I
internalization for degradation and thereby diminish
antigen display on the cell surface.268 Indeed, in vivo
studies have primarily found enhanced CD8+ T cell
responses in mice with defective autophagy in antigen-
presenting cells268,269,270 A potential mechanism leading
to such increased CD8+ T cell expansions is that, in the
absence of autophagy, more substrate becomes available
for canonical MHC class I loading271 or by decreased
endocytosis and degradation of cell surface MHC class I
molecules.268 Thus, defective autophagy in skeletal muscle
fibers could drive increased MHC class I expression and
CD8+ T cell accumulation.
Brain biopsies of early (preclinical) and moderate stage
AD patients exhibit impaired neuronal autophagic activity
represented by increased numbers of LC3+ autophago-
somes and diminished fusion of these vesicles with lyso-
somes into autolysosomes.272 Moreover, autophagosomes
purified from an APP695-transfected murine fibroblast-like
cell line, contain copious amounts of APP, PS1, nicastrin,
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and c-secretase complex with functional amyloidogenesis
at the site of the autophagosome, resulting in Ab1-40 and
Ab1-42 peptides.
272 Importantly, these generated peptides
were not instable intermediates as they did not seem to
undergo additional cleavage after further 24 h incubation
in autophagosomes as opposed to their Ab-specific clea-
vage in lysosomal fractions.272 In line with this, in vitro
exposure of human muscle cells to autophagy inducers
TNF-a or rapamycin leads to marked increase of intracel-
lular APP and Ab oligomers. Specific siRNA-mediated
knockdown of the essential autophagy gene Atg12 prevents
the assembly of autophagosomes and abbrogates TNF-a-
mediated accumulation of Ab in muscle cells.273 These
findings appear to be in contrast to a subsequent study in
which Nogalska et al. report increased accumulation of Ab
oligomers upon inhibition of autophagy in cultured
human myofibers.187 However, these results should be
carefully interpreted since inhibition of autophagy was car-
ried out by using chloroquine and bafilomycin A1 (a speci-
fic inhibitor of the V-ATPase), both of which lack
specificity and are believed to inhibit lysosomal acidifica-
tion and thereby subsequent fusion of the autophagosome
with lysosomes rather than the assembly of the autophago-
some,274 which results in impaired autophagosome matu-
ration and accumulation of autophagosomes. In the case
of bafilomycin A1, the actual inhibitory potential with
regard to blocking autophagosome-lysosome fusion has
been doubted previously and bafilomycin A1 increases LC3
lipidation to a similar degree as autophagy-inducer rapa-
mycin.275,276 Conversely, others have confirmed increased
Ab generation associated with preceding autophagosome
accumulation in different mammalian cell types.277–279
Autophagy and the proteasomal system are unequivo-
cally colligated in their endeavor to keep proteostasis.
Selective transport of target molecules toward degrading
vesicles or macromolecular structures like the proteasome
requires multifunctional adaptor molecules. Polyubiquity-
lated proteins can be targeted via p62/SQSTM1 or neigh-
bor of BRCA1 gene 1 (NBR1) for degradation via the
proteasomal or the autophagy/lysosomal system.280–283 In
IBM muscle, both p62/SQSTM1 and NBR1 are upregu-
lated on protein and mRNA level and colocalize with
phosphorylated tau in protein aggregates.222,284 The cargo
protein p62/SQSTM1 can bind Lys63-linked ubiquitin
and phosphorylation at Ser403 of p62 enhances the bind-
ing affinity of p62 to ubiquitin.285 A recent study demon-
strates that aggregated p62/SQSTM1 is largely
phosphorylated at Ser403 in muscles of IBM patients and
Lys63-linked ubiquitin colocalized with p62/SQSTM1
aggregates, suggesting impaired initiation of selective
autophagy targeting ubiquitinated proteins.286
Generally, as a result of active cellular synthesis pro-
cesses, an unpreventable fraction of misfolded proteins,
the so-called defective ribosomal products (DRiPs) arise
and need to be subsequently cleared from the cytosol in
order to avoid cell stress and cytotoxicity. In one pro-
posed model, DRiPs are polyubiquitylated and subse-
quently subjected to proteasomal degradation. The
resulting peptides are fed into the MHC class I presenting
pathway and will be surveilled by CD8+ T cells.287 Upon
impairment of autophagy in HeLa cells, its substrates
accumulate in p62/SQSTM1-positive aggresome-like
induced structures and are fed into the proteasomal path-
way with subsequent presentation via MHC class I.271
Differential activity of autophagy might, therefore, shape
the peptide pool presented on MHC class I and it is
tempting to speculate that impairment of this control
mechanism in IBM muscle abets invasion of myoaggres-
sive immune cells.
Differential diagnosis can be challenging facing the
PM-IBM spectrum of T cell-rich inflammatory myopa-
thies. The recent advances in identifying autophagy as a
relevant malregulated process in IBM has already yielded
practical application in that using a combination of LC3
(sensitive) and transactive response DNA-binding protein
43 kDa (TDP-43) (specific) stainings was found to be
effective in discriminating IBM from PM.288
Interrelationship between
inflammation, cell stress and
myodegeneration
It has been proposed that muscle invasion of peripheral
immune cells and progressive myodegeneration are closely
linked in the development of IBM.289 However, the pre-
cise sequence of events remains incompletely understood.
In IBM muscle, but not in PM or DM, IL-1b is spatially
associated with Ab and degenerative changes positively
correlate with the degree of inflammation in IBM
patients.290 Furthermore, exposure of human myotubes to
IL-1b leads to upregulation of APP and accumulation of
Ab in vitro and this effect can be synergistically promoted
by composite exposure with IFNc.290 Pro-inflammatory
stimuli, such as IL-1b, TNF-a, and IFNc augment expres-
sion of inducible nitric oxide synthase (iNOS), and com-
posite exposure of murine muscle cells with IFNc and Ab
peptides provoke robust nitric oxide (NO) produc-
tion.291–293 Expression of iNOS in IBM muscle has been
reported several years ago294 and more recently confirmed
and extended: iNOS expression and concomitant NO
production was enhanced in IBM muscle compared to
DM and PM muscle.295 More importantly, nitrotyrosine,
the product of tyrosine nitration in the presence of
metabolically active NO, colocalized with Ab in IBM
muscle fibers. In vitro assays revealed that exposure of
primary human muscle cells to IL-1b together with IFNc
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elicits strong NO production, followed by necrotic cell
death.295 Conversely, the pharmacological inhibition of
iNOS prevented cytokine-mediated accumulation of Ab
and necrotic cell death indicative of iNOS being at the
interface of proinflammatory stress and degenerative
changes in IBM muscle. Taken together, these data
revealed a crucial role for IBM-relevant pro-inflammatory
mediators in the promotion of amyloidogenesis in the
muscle. In double-transgenic MCK-APP/PS1 mice, an
animal model for IBM, chronic exposure to inflammatory
stimuli significantly increases deposition of the insoluble
and cytotoxic Ab1-42 in myofibers whereas Ab1-40 levels
remain unchanged. In addition, chronic inflammation by
virtue of TNF-a, IL-6, and IL-1b, facilitated and enhanced
GSK3b-mediated phosphorylation of tau in myofibers
resulting in pronounced motor impairment.210
The small heat shock protein aB crystallin is constitu-
tively expressed in human skeletal muscle cells, binds mis-
folded proteins in order to avert their aggregation and its
expression is sensitive to TNF-a-mediated induction.296–
298 During AD pathology expression of aB crystallin is
increased in CNS resident glial cells that are found in
close spatial proximity to extracellular amyloid and neu-
rofibrillary tangles.299 Human myotubes exposed to the
combination of IL-1b and IFNc show marked induction
of aB crystallin and APP.300 More importantly, expression
of aB crystallin is increased in IBM muscle (and to a
lower degree in PM and DM) not only in muscle fibers
with structural abnormalities but also in normal appear-
ing myofibers, suggesting an early event in IBM patho-
genesis that links pro-inflammatory cell stress to
accumulation of aberrant proteins.300,301
The neuronal receptor for advanced glycation endpro-
duct (RAGE) has been implicated in a pro-inflammatory
pathway of AD pathology in that binding of its ligand Ab
facilitates NFjB-dependent M-GSF production and subse-
quent chemotaxis of myeloid cells.302 High mobility
group box 1 (HMGB1), another ligand for RAGE, is a
nuclear DNA-binding protein that can be actively secreted
or passively released upon necrotic cell death (but not
upon apoptosis) and exert proinflammatory effects by
triggering myeloid cells to secrete substantial amounts of
TNF-a, IL-1b, IL-6, IL-8, macrophage inflammatory pro-
tein (MIP)-1a, MIP-1b.303–305 HMGB1 is expressed and
released by human skeletal muscle cells upon muscle
injury and via binding to RAGE expressed on the surface
of myoblasts faciliates myogenesis and muscle regenera-
tion.306,307
RAGE, in association with reactive oxygen species- and
NFjB-dependent pathways and HMGB1 are overex-
pressed in myositis.308–310 In IBM muscle, RAGE and
HMGB1 colocalize with Ab and neurofilament/tau
and composite exposure of human muscle cells with IFNc
and IL-1b leads to cytoplasmic translocation and subse-
quent release of HMGB1 into the extracellular space.310
Furthermore, exposure of human muscle cells to exoge-
nous HMGB1 is equally pontent in triggering Ab accu-
mulation as IFNc/IL-1b.310 These findings strongly
suggest a facilitator role for the HMGB1-RAGE-Ab-axis
in interconnecting inflammatory and degenerative events
during IBM.310
In a possible pathological setting, necrosis-undergoing
myofibers might release vast amounts of HMGB1. Exces-
sive presence of this mediator might overwrite its pro-
myoregenerative function and rather promote protein
aggregation in RAGE-expressing muscle cells as well as
release of proinflammatory cytokines by infiltrating
immune cells. This cascade perpetuates and amplifies the
myoaggressive microenvironment in IBM.
Collectively, mounting evidence from in vitro studies,
animal models, and human muscle samples suggests
that inflammation in IBM can trigger and sustain cell
stress in skeletal muscle with subsequent accumulation
of unwanted proteins and irreversible muscle fiber dam-
age.
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